Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up.

Onuma AE, Beal EW, Nabhan F, Hughes T, Farrar WB, Phay J, Ringel MD, Kloos RT, Shirley LA.

Ann Surg Oncol. 2019 Feb 28. doi: 10.1245/s10434-019-07263-5. [Epub ahead of print]

PMID:
30820785
2.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
3.

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE.

JAMA Oncol. 2018 Nov 8. doi: 10.1001/jamaoncol.2018.4616. [Epub ahead of print]

PMID:
30419129
4.

Transcriptional targeting of oncogene addiction in medullary thyroid cancer.

Valenciaga A, Saji M, Yu L, Zhang X, Bumrah C, Yilmaz AS, Knippler CM, Miles W, Giordano TJ, Cote GJ, Ringel MD.

JCI Insight. 2018 Aug 23;3(16). pii: 122225. doi: 10.1172/jci.insight.122225. eCollection 2018 Aug 23.

5.

Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.

Segkos K, Porter K, Senter L, Ringel MD, Nabhan FA.

Horm Cancer. 2018 Dec;9(6):433-439. doi: 10.1007/s12672-018-0345-6. Epub 2018 Aug 7.

PMID:
30088223
6.

Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131I Therapy for Differentiated Thyroid Cancer.

Gomes-Lima CJ, Wu D, Kharazi PH, Khojekar GJ, Ringel MD, Vetter RJ, Bloom G, Burman KD, Wartofsky L, Van Nostrand D.

Thyroid. 2017 Dec;27(12):1558-1565. doi: 10.1089/thy.2017.0124.

PMID:
29132255
7.

Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.

Valenciaga A, Grubbs EG, Porter K, Wakely PE Jr, Williams MD, Cote GJ, Vasko VV, Saji M, Ringel MD.

Thyroid. 2017 Dec;27(12):1523-1533. doi: 10.1089/thy.2017.0113.

8.

United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin.

Kahaly GJ, Algeciras-Schimnich A, Davis TE, Diana T, Feldkamp J, Karger S, König J, Lupo MA, Raue F, Ringel MD, Sipos JA, Kratzsch J.

Clin Chem. 2017 Sep;63(9):1489-1496. doi: 10.1373/clinchem.2016.270009. Epub 2017 Jul 7.

9.

Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model.

Rossfeld KK, Justiniano SE, Ding H, Gong L, Kothandaraman S, Sawant D, Saji M, Wright CL, Kirschner LS, Ringel MD, Tweedle MF, Phay JE.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3268-3277. doi: 10.1210/jc.2017-00573.

10.

RCAN1-4 is a thyroid cancer growth and metastasis suppressor.

Wang C, Saji M, Justiniano SE, Yusof AM, Zhang X, Yu L, Fernández S, Wakely P Jr, La Perle K, Nakanishi H, Pohlman N, Ringel MD.

JCI Insight. 2017 Mar 9;2(5):e90651. doi: 10.1172/jci.insight.90651.

11.

A genome-wide association study yields five novel thyroid cancer risk loci.

Gudmundsson J, Thorleifsson G, Sigurdsson JK, Stefansdottir L, Jonasson JG, Gudjonsson SA, Gudbjartsson DF, Masson G, Johannsdottir H, Halldorsson GH, Stacey SN, Helgason H, Sulem P, Senter L, He H, Liyanarachchi S, Ringel MD, Aguillo E, Panadero A, Prats E, Garcia-Castaño A, De Juan A, Rivera F, Xu L, Kiemeney LA, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Kristvinsson H, Netea-Maier RT, Jonsson T, Mayordomo JI, Plantinga TS, Hjartarson H, Hrafnkelsson J, Sturgis EM, Thorsteinsdottir U, Rafnar T, de la Chapelle A, Stefansson K.

Nat Commun. 2017 Feb 14;8:14517. doi: 10.1038/ncomms14517.

12.
13.

Germline compound heterozygous poly-glutamine deletion in USF3 may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma.

Ni Y, Seballos S, Fletcher B, Romigh T, Yehia L, Mester J, Senter L, Niazi F, Saji M, Ringel MD, LaFramboise T, Eng C.

Hum Mol Genet. 2017 Jan 15;26(2):243-257. doi: 10.1093/hmg/ddw382.

14.

Thyroid nodules and cancer management guidelines: comparisons and controversies.

Nabhan F, Ringel MD.

Endocr Relat Cancer. 2017 Feb;24(2):R13-R26. doi: 10.1530/ERC-16-0432. Epub 2016 Dec 13. Review.

15.

Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.

Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos RT, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang SM.

J Clin Endocrinol Metab. 2016 Nov;101(11):4085-4093. Epub 2016 Aug 17.

16.

Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.

Liyanarachchi S, Li W, Yan P, Bundschuh R, Brock P, Senter L, Ringel MD, de la Chapelle A, He H.

J Clin Endocrinol Metab. 2016 Nov;101(11):4005-4013. Epub 2016 Jul 26.

17.

Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies.

Azmat U, Porter K, Senter L, Ringel MD, Nabhan F.

Thyroid. 2017 Jan;27(1):74-80. doi: 10.1089/thy.2016.0210. Epub 2016 Nov 9.

18.

Genetic variants in thyroid cancer distant metastases.

Justiniano SE, McElroy JP, Yu L, Yilmaz AS, Coombes KR, Senter L, Nagy R, Wakely P Jr, Volinia S, Vinco M, Giordano TJ, Croce CM, Saji M, Ringel MD.

Endocr Relat Cancer. 2016 Oct;23(10):L33-6. doi: 10.1530/ERC-16-0351. Epub 2016 Aug 19. No abstract available.

19.

Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.

Jendrzejewski J, Liyanarachchi S, Nagy R, Senter L, Wakely PE, Thomas A, Nabhan F, He H, Li W, Sworczak K, Ringel MD, Kirschner LS, de la Chapelle A.

Thyroid. 2016 Sep;26(9):1276-84. doi: 10.1089/thy.2015.0665. Epub 2016 Jul 22.

20.

Primary Cell Culture Systems for Human Thyroid Studies.

Wang Y, Li W, Phay JE, Shen R, Pellegata NS, Saji M, Ringel MD, de la Chapelle A, He H.

Thyroid. 2016 Aug;26(8):1131-40. doi: 10.1089/thy.2015.0518. Epub 2016 Jul 6.

21.

Ernest L. Mazzaferri, SR., MD 1936-2013.

Goldberg R, Ringel MD.

Trans Am Clin Climatol Assoc. 2015;126:xcix-ci. No abstract available.

22.

Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target.

Shirley LA, McCarty S, Yang MC, Saji M, Zhang X, Phay J, Ringel MD, Chen CS.

Surgery. 2016 Jan;159(1):163-70. doi: 10.1016/j.surg.2015.10.016. Epub 2015 Nov 6.

23.

Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.

Bible KC, Cote GJ, Demeure MJ, Elisei R, Jhiang S, Ringel MD; International Thyroid Oncology Group Correlative Science Committee.

J Clin Endocrinol Metab. 2015 Dec;100(12):4387-95. doi: 10.1210/jc.2015-2818. Epub 2015 Sep 29.

24.

Anaplastic Thyroid Carcinoma, Version 2.2015.

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

25.

Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments.

Guzman N, Agarwal K, Asthagiri D, Yu L, Saji M, Ringel MD, Paulaitis ME.

Mol Cancer Res. 2015 May;13(5):891-901. doi: 10.1158/1541-7786.MCR-14-0533. Epub 2015 Feb 26.

26.

A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.

Plews RL, Mohd Yusof A, Wang C, Saji M, Zhang X, Chen CS, Ringel MD, Phay JE.

J Clin Endocrinol Metab. 2015 May;100(5):E748-56. doi: 10.1210/jc.2014-1777. Epub 2015 Feb 24.

27.

Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer.

Ni Y, Seballos S, Ganapathi S, Gurin D, Fletcher B, Ngeow J, Nagy R, Kloos RT, Ringel MD, LaFramboise T, Eng C.

Endocr Relat Cancer. 2015 Apr;22(2):121-30. doi: 10.1530/ERC-14-0537.

28.

Thyroid carcinoma, version 2.2014.

Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80; quiz 1680.

PMID:
25505208
29.

Integrated genomic characterization of papillary thyroid carcinoma.

Cancer Genome Atlas Research Network.

Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.

30.

Genetic predisposition for nonmedullary thyroid cancer.

Nagy R, Ringel MD.

Horm Cancer. 2015 Feb;6(1):13-20. doi: 10.1007/s12672-014-0205-y. Epub 2014 Oct 22. Review.

PMID:
25338077
31.

BRAF activates and physically interacts with PAK to regulate cell motility.

McCarty SK, Saji M, Zhang X, Knippler CM, Kirschner LS, Fernandez S, Ringel MD.

Endocr Relat Cancer. 2014;21(6):865-77. doi: 10.1530/ERC-14-0424. Epub 2014 Sep 16.

32.

Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.

Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, Kirschner JM, Parlow AF, Saji M, Jarjoura D, Ringel MD, La Perle KM, Kirschner LS.

J Clin Endocrinol Metab. 2014 May;99(5):E804-12. doi: 10.1210/jc.2013-3101. Epub 2014 Feb 10.

33.

SDHB gene mutation in a carotid body paraganglioma: case report and review of the paraganglioma syndromes.

Peterson LA, Litzendorf M, Ringel MD, Vaccaro PS.

Ann Vasc Surg. 2014 Jul;28(5):1321.e9-12. doi: 10.1016/j.avsg.2013.12.012. Epub 2014 Feb 5. Review.

PMID:
24509376
34.

Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.

Lakshmanan A, Doseff AI, Ringel MD, Saji M, Rousset B, Zhang X, Jhiang SM.

Thyroid. 2014 May;24(5):878-87. doi: 10.1089/thy.2013.0614. Epub 2014 Mar 6.

35.

Development of a calcium-sensing receptor molecular imaging agent.

Yusof AM, Kothandaraman S, Zhang X, Saji M, Ringel MD, Tweedle MF, Phay JE.

Surgery. 2013 Dec;154(6):1378-84; discussion 1384. doi: 10.1016/j.surg.2013.06.044.

36.

Metastatic mechanisms in follicular cell-derived thyroid cancer.

Phay JE, Ringel MD.

Endocr Relat Cancer. 2013 Oct 14;20(6):R307-19. doi: 10.1530/ERC-13-0187. Print 2013 Dec. Review.

37.

Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer.

Ding H, Yusof AM, Kothandaraman S, Saji M, Wang C, Kumar K, Milum K, Carleton M, Pan X, Ringel MD, Tweedle MF, Phay JE.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1722-9. doi: 10.1210/jc.2013-1756. Epub 2013 Sep 12.

38.

Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.

Ringel MD, Nabhan F.

J Clin Endocrinol Metab. 2013 Aug;98(8):3104-10. doi: 10.1210/jc.2013-1412. Review.

39.

Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.

Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MD.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1314-22. doi: 10.1210/jc.2012-3937. Epub 2013 May 24. Erratum in: J Clin Endocrinol Metab. 2016 Mar;101(3):1314.

40.

Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.

Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R, Hoag K, Wen B, Ploski R, Ringel MD, Kozłowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle A.

Thyroid. 2013 Dec;23(12):1532-40. doi: 10.1089/thy.2013.0102. Epub 2013 Aug 29.

41.

SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.

He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, Sebastian N, Wen B, Puch Z, Kalemba M, Stachlewska E, Czetwertynska M, Dlugosinska J, Dymecka K, Ploski R, Krawczyk M, Morrison PJ, Ringel MD, Kloos RT, Jazdzewski K, Symer DE, Vieland VJ, Ostrowski M, Jarząb B, de la Chapelle A.

J Clin Endocrinol Metab. 2013 May;98(5):E973-80. doi: 10.1210/jc.2012-3823. Epub 2013 Mar 28.

42.

In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.

Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD, Kloos RT.

Thyroid. 2013 Feb;23(2):185-93. doi: 10.1089/thy.2012.0327.

43.

PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.

He X, Saji M, Radhakrishnan D, Romigh T, Ngeow J, Yu Q, Wang Y, Ringel MD, Eng C.

J Clin Endocrinol Metab. 2012 Nov;97(11):E2179-87. doi: 10.1210/jc.2012-1991. Epub 2012 Sep 7.

44.

Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells.

Liu YY, Zhang X, Ringel MD, Jhiang SM.

Endocr Relat Cancer. 2012 May 3;19(3):291-304. doi: 10.1530/ERC-11-0288. Print 2012 Jun.

45.

Discovery of common variants associated with low TSH levels and thyroid cancer risk.

Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, Jonasdottir A, Sigurdsson A, Stacey SN, Johannsdottir H, Helgadottir HT, Li W, Nagy R, Ringel MD, Kloos RT, de Visser MC, Plantinga TS, den Heijer M, Aguillo E, Panadero A, Prats E, Garcia-Castaño A, De Juan A, Rivera F, Walters GB, Bjarnason H, Tryggvadottir L, Eyjolfsson GI, Bjornsdottir US, Holm H, Olafsson I, Kristjansson K, Kristvinsson H, Magnusson OT, Thorleifsson G, Gulcher JR, Kong A, Kiemeney LA, Jonsson T, Hjartarson H, Mayordomo JI, Netea-Maier RT, de la Chapelle A, Hrafnkelsson J, Thorsteinsdottir U, Rafnar T, Stefansson K.

Nat Genet. 2012 Jan 22;44(3):319-22. doi: 10.1038/ng.1046.

46.

MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.

Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A, Kloos RT, He H.

Thyroid. 2012 Jan;22(1):9-16. doi: 10.1089/thy.2011.0081. Epub 2011 Dec 2.

47.

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M, Ringel MD.

Endocr Relat Cancer. 2012 Jan 9;19(1):29-38. doi: 10.1530/ERC-11-0155. Print 2012 Feb.

48.

Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53.

Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, Ringel MD, Eng C.

Hum Mol Genet. 2012 Jan 15;21(2):300-10. doi: 10.1093/hmg/ddr459. Epub 2011 Oct 6.

49.

Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.

Jendrzejewski J, Tomsic J, Lozanski G, Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT, Heerema NA, de la Chapelle A.

J Clin Endocrinol Metab. 2011 Nov;96(11):E1876-80. doi: 10.1210/jc.2011-1643. Epub 2011 Sep 7.

50.

Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma.

Arab K, Smith LT, Gast A, Weichenhan D, Huang JP, Claus R, Hielscher T, Espinosa AV, Ringel MD, Morrison CD, Schadendorf D, Kumar R, Plass C.

Carcinogenesis. 2011 Oct;32(10):1467-73. doi: 10.1093/carcin/bgr138. Epub 2011 Jul 18.

Supplemental Content

Loading ...
Support Center